"Called Wegovy HD, the higher-dose drug helped participants in a study lose about 19% of their body weight, or almost 47 pounds, versus about 16% of body weight, or 39 pounds with the lower dose over almost 17 months."
"The higher dose was developed because while the 2.4-milligram shot is effective, "some individuals do not reach their therapeutic goals" at that dose, according to results published last year in the medical journal Lancet Diabetes & Endocrinology."
"The U.S. Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo Nordisk's semaglutide. Previously, the highest approved dose of the drug, taken as a weekly shot, was 2.4 milligrams."
The FDA approved a new 7.2-milligram dose of semaglutide, marketed as Wegovy HD, for obesity treatment. This higher dose represents a significant increase from the previous maximum of 2.4 milligrams. The approval occurred through accelerated review, completed in 54 days. Clinical studies demonstrated that the higher dose produced greater weight loss results, with participants losing approximately 19% of body weight over 17 months compared to 16% with the lower dose. The new formulation will become available at U.S. pharmacies in April. European regulators had previously approved this higher-dose version in February. The development of the increased dose addresses limitations of the standard dose, as some patients fail to achieve therapeutic weight loss goals at 2.4 milligrams.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]